Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.82 |
| ▸ | CCND1 | P24385 | 4/20 | 0.82 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5989829 | 0.86 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL9703488 | 0.86 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL17822342 | 0.85 | CDK4 (0.76) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL29379363 | 0.85 | CDK4 (0.76) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL4869090 | 0.84 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL24398975 | 0.82 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL725812 | 0.82 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL9702210 | 0.82 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL6396944 | 0.82 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL19748097 | 0.82 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119269609-A | Method for qualitatively and quantitatively analyzing novel psychoactive substances in tobacco tar by in-situ ionization-quadrupole time-of-flight mass spectrometry | 岛津企业管理（中国）有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-114478389-A | Isotopic psychoactive substance labeled compound, preparation method, application and application thereof | 公安部第三研究所 | 2022-05-13 | — | — | CN | claimed |
| CN-113325088-A | Isotope mental active substance labeled compound and preparation method and application thereof | 无锡诺平医药科技有限公司 | 2021-08-31 | — | — | CN | claimed |
| CN-113321701-A | Isotope mental active substance labeled compound and preparation method and application thereof | 无锡诺平医药科技有限公司 | 2021-08-31 | — | — | CN | claimed |
| CN-120009249-A | Synthetic cannabinoid classification method | 中国科学院新疆理化技术研究所 | 2025-05-16 | — | — | CN | disclosed |
| CN-119269609-A | Method for qualitatively and quantitatively analyzing novel psychoactive substances in tobacco tar by in-situ ionization-quadrupole time-of-flight mass spectrometry | 岛津企业管理（中国）有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC (CA) | 2023-08-31 | — | — | US | disclosed |
| CN-114478389-A | Isotopic psychoactive substance labeled compound, preparation method, application and application thereof | 公安部第三研究所 | 2022-05-13 | — | — | CN | disclosed |
| CN-113325088-A | Isotope mental active substance labeled compound and preparation method and application thereof | 无锡诺平医药科技有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-113321701-A | Isotope mental active substance labeled compound and preparation method and application thereof | 无锡诺平医药科技有限公司 | 2021-08-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | CNR1, CNR2, SARS1 | CDK4 2566/4885CCND1 4193/4885HTR2A 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.